Edoxaban has similar efficacy to enoxaparin for thromboprophylaxis after THA .
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan
J Arthroplasty. 2014 Dec;29(12):2439-46.264 patients scheduled for total hip arthroplasty were randomized to one of three groups: a group which received 15mg edoxaban daily, a group which received 30mg edoxaban daily, or a group which received 20mg of enoxaparin sodium twice daily. This was done to determine the safety, efficacy, and optimal dosage regimen of edoxaban as compared to enoxaparin in patients undergoing total hip arthroplasty. Factors such as the incidence of thromboembolic events, bleeding, and adverse drug reactions were evaluated over a 14 day postoperative period. The results demonstrated that edoxaban is a safe and efficacious alternative to enoxaparin sodium, and that a 30mg daily dose of edoxaban is appropriate.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
